Yimei Shen1, Xiaohua Yang1, Xiaojun Han1, Wei Xi1, Lihua Jiang1, Shuqin Wang1, Haifeng Zhong1, Yunjuan Gu2. 1. Department of Endocrinology, Haian Hospital Affiliated to Nantong University Nantong 226600, Jiangsu Province, China. 2. Department of Endocrinology, Affiliated Hospital of Nantong University Nantong 226601, Jiangsu Province, China.
Abstract
OBJECTIVE: To determine the effect of glucagon-like peptide-1 receptor agonist (GLP-1RA) on cases with type 2 diabetes mellitus (T2DM) in terms of insulin dosage and blood glucose (BG) control. METHODS: A total of 180 patients with T2DM admitted to our hospital between March 2016 and March 2019 were selected and assigned to a GLP-1RA group (GLP-1 group, n=100) and a control group (control group, n=80). Patients in the GLP-1 group were treated with GLP-1RA combined with insulin, while those in the other group were treated with insulin alone. The following items of each patient were determined: Body weight, body mass index (BMI), waist circumference, blood pressure (BP), BG-related indexes, insulin dosage, insulin resistance index, cardiovascular function, serum lipid-related indexes, adverse reactions, total effective rate, and treatment satisfaction. RESULTS: Compared with the control group, the GLP-1 group showed a decrease in weight, BMI, waist circumference, BP, BG-related indexes, and insulin resistance index, consumed less insulin dosage, and also showed a decline in cardiovascular function, serum lipid-related indexes (total cholesterol (TC), triacylglycerol (TG), and low density lipoprotein cholesterol (LDL-C)), an increase in high density lipoprotein cholesterol (HDL-C), less adverse reactions, and higher total effective rate and treatment satisfaction. CONCLUSION: GLP-1RA contributes to better BG control of patients with T2DM, and it reduces the insulin dosage required during operation for its stimulation to the production of insulin. AJTR
OBJECTIVE: To determine the effect of glucagon-like peptide-1 receptor agonist (GLP-1RA) on cases with type 2 diabetes mellitus (T2DM) in terms of insulin dosage and blood glucose (BG) control. METHODS: A total of 180 patients with T2DM admitted to our hospital between March 2016 and March 2019 were selected and assigned to a GLP-1RA group (GLP-1 group, n=100) and a control group (control group, n=80). Patients in the GLP-1 group were treated with GLP-1RA combined with insulin, while those in the other group were treated with insulin alone. The following items of each patient were determined: Body weight, body mass index (BMI), waist circumference, blood pressure (BP), BG-related indexes, insulin dosage, insulin resistance index, cardiovascular function, serum lipid-related indexes, adverse reactions, total effective rate, and treatment satisfaction. RESULTS: Compared with the control group, the GLP-1 group showed a decrease in weight, BMI, waist circumference, BP, BG-related indexes, and insulin resistance index, consumed less insulin dosage, and also showed a decline in cardiovascular function, serum lipid-related indexes (total cholesterol (TC), triacylglycerol (TG), and low density lipoprotein cholesterol (LDL-C)), an increase in high density lipoprotein cholesterol (HDL-C), less adverse reactions, and higher total effective rate and treatment satisfaction. CONCLUSION: GLP-1RA contributes to better BG control of patients with T2DM, and it reduces the insulin dosage required during operation for its stimulation to the production of insulin. AJTR
Authors: Juan Pablo Frias; Edward J Bastyr; Louis Vignati; Matthias H Tschöp; Christophe Schmitt; Klara Owen; Rune Haubo Christensen; Richard D DiMarchi Journal: Cell Metab Date: 2017-08-01 Impact factor: 27.287
Authors: Lennart Tonneijck; Marcel H A Muskiet; Mark M Smits; Petter Bjornstad; Mark H H Kramer; Michaela Diamant; Ewout J Hoorn; Jaap A Joles; Daniël H van Raalte Journal: Diabetes Obes Metab Date: 2018-02-20 Impact factor: 6.577
Authors: Lennart Tonneijck; Mark M Smits; Marcel H A Muskiet; Trynke Hoekstra; Mark H H Kramer; A H Jan Danser; Michaela Diamant; Jaap A Joles; Daniël H van Raalte Journal: Diabetologia Date: 2016-04-01 Impact factor: 10.122